HC Wainwright & Co. Maintains Buy on Verona Pharma, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Verona Pharma (NASDAQ:VRNA) and raised the price target from $32 to $36.
June 27, 2024 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Verona Pharma and raised the price target from $32 to $36.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100